ArticleNews reportPHN-05512026-11-02 00:42 CT

Buy Ajanta Pharma; target of Rs 4250: Prabhudas Lilladher

Source · TradingView

TLDR

Prabhudas Lilladher maintained a Buy rating on Ajanta Pharma with a revised target of Rs 4,250 per share, citing strong earnings growth. The brokerage also highlighted Ajanta’s recent agreement with Biocon to market semaglutide in 26 countries as a fit with its existing business.

01—Key points

01The brokerage reported Q2FY27 EBITDA rose 47% year over year to INR 5.43 billion, exceeding its estimates.
02Ajanta’s in-licensing agreement with Biocon covers semaglutide marketing in 26 countries across rest-of-world markets.
03The brokerage raised its FY28 and FY29 earnings-per-share estimates by 3–6%.

Why it matters Editorial

The report highlights a semaglutide marketing agreement spanning 26 countries, although its main focus is Ajanta Pharma’s financial outlook.

Read the original at TradingView↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.